Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia. - Wikidata - awgldk - TriplyDB

Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.

Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.

http://www.wikidata.org/entity/Q33749036

about

Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.

http://www.wikidata.org/entity/Q33749036

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.

@ast

Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.

@en

type

label

Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.

@ast

Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.

@en

prefLabel

Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.

@ast

Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.

@en

P1433

Q33749036-5B8E5A51-72F4-4E17-B6AF-64C28CB19DAF

P1476

Q33749036-3DF766CF-A626-4F39-9A1A-BC8AE042FF75

P2093

Q33749036-25E3D09C-AABC-4726-9E18-4CBF055CFF16

Q33749036-35D8C686-0BD4-4A36-9A27-E6E25062A442

Q33749036-A66D0774-390B-4686-BFA6-058FBFB940A9

Q33749036-C18E6201-56DB-449F-A9ED-2DD3DC1F923F

Q33749036-D0BC392F-31FB-4849-9D01-ACEF02575A24

P2860

Q33749036-00E7252A-D4B9-4FD9-8922-808D537072B6

Q33749036-02378928-83C0-4445-B76A-5A043601D1B6

Q33749036-0CD9B2BA-F412-4C29-A0D7-A73B53EC659F

Q33749036-156384D9-B266-46F8-85E9-0A90E1BDFD27

Q33749036-16D87A4F-D1E4-4050-A8A0-8CF148C281CD

Q33749036-20042B8A-1405-45E3-B721-2A1162677069

Q33749036-25D9FE70-743B-47BE-B44C-7433A52EB6FA

Q33749036-2C3C9ECE-8701-4A9E-AF31-6AAB0305F393

Q33749036-31E13FF5-8FEE-4ED9-A630-05D61C120080

Q33749036-377B5EBF-8F7D-4BFD-AC9F-096919F55520

P304

Q33749036-30672EFF-0AA2-4F94-A2E6-0790B7C9F84C

P31

Q33749036-DFA1FCFF-0D68-4DB9-89C1-4D9456E79992

P356

Q33749036-6696DBA2-A675-407A-B4EA-D15B259978DD

P433

Q33749036-1F22F663-D9FE-4230-8112-9A072091E902

P478

Q33749036-1869691A-8F62-429B-9AC0-DDFAB4D19206

P50

Q33749036-632F4B88-4ED1-4004-BB37-48D82678BE2B

Q33749036-E952EA8B-7E16-4E43-B853-63B56820EBAA

P577

Q33749036-4DC59BE2-FCE7-4123-850F-5008E52D7038

P698

Q33749036-E486A9CA-E379-4E2E-A136-B843BC49F3B3

P932

Q33749036-A0415C1C-6A08-480E-A0A8-C32F68750FA0

P356

ACSOMEGA.7B00144

P1433

P1476

Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia

@en

P2093

Jae Yoon Jeon

http://www.w3.org/2001/XMLSchema#string

Jamie A Jarusiewicz

http://www.w3.org/2001/XMLSchema#string

Lei Yang

http://www.w3.org/2001/XMLSchema#string

Michele C Connelly

http://www.w3.org/2001/XMLSchema#string

Yizhe Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Structural and functional alterations of FLT3 in acute myeloid leukemia

Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor

Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications

Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers

Development of o -Chlorophenyl Substituted Pyrimidines as Exceptionally Potent Aurora Kinase Inhibitors

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

P304

1985-2009

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ACSOMEGA.7B00144

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Sharyn D. Baker

P577

2017-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28580438

http://www.w3.org/2001/XMLSchema#string

P932

5452050

http://www.w3.org/2001/XMLSchema#string